Glenmark Pharmaceuticals’ wholly owned subsidiary -- Glenmark Specialty S.A. has launched RYALTRIS Nasal Spray in Brazil for the treatment of moderate to severe symptoms associated with allergic rhinitis (AR) in adults and adolescents of 12 years of age and older. The launch follows regulatory approval granted by the Brazilian Health Regulatory Agency, Agencia Nacional de Vigilancia Sanitaria (ANVISA) earlier this year.
The launch of RYALTRIS introduces the first olopatadine-containing intranasal combination therapy in Brazil, combining an antihistamine (olopatadine hydrochloride) and a corticosteroid (mometasone furoate) in a single nasal spray. This offers a differentiated dual-action treatment option for symptoms associated with allergic rhinitis.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
